# Seven Bridges

> Seven Bridges builds cloud software and bioinformatics services for researchers handling genomic and other biomedical data. Its platform combines data storage, reproducible analysis workflows, collaboration and scientific support for government programs, academic groups, biopharma companies and diagnostic laboratories. Acquired by Summa Equity and combined with Pierian and UgenTec to form Velsera in 2023, Seven Bridges continues as a named platform within that business.

- **Founded:** 2009
- **Headquarters:** Boston, United States
- **Founders:** Deniz Kural (Co-founder and founding CEO), Igor Bogicevic (Co-founder and former CTO), James Sietstra (Co-founder and former president), Doug Colton (Original co-founder; early finance and legal work, according to his retrospective), John Sheffield (Original co-founder; early marketing and networking, according to Doug Colton’s retrospective)
- **Products:** Seven Bridges Platform, Cancer Genomics Cloud, GRAF, RHEO, ARIA
- **Notable:** Awarded a USD 5.8 million NCI Cancer Genomics Cloud pilot contract in 2014., Received an approximately GBP 1.95 million UK SBRI award for Graph Genome development in 2015., Named to MIT Technology Review’s 2016 50 Smartest Companies list, as reported in its press archive.

## Products & services

- **Seven Bridges Platform** — Cloud bioinformatics environment for storing data, building and executing workflows, collaborating and recording analysis provenance. Remains a named Velsera product.
- **Cancer Genomics Cloud** — NCI-funded research platform that places public cancer datasets beside analysis tools and on-demand computing; pilot launched in 2016.
- **GRAF** — Graph-reference tools and workflows for genomic alignment and variant analysis, including population-tailored references.
- **RHEO** — Workflow automation built on the Seven Bridges Platform, integrating input data, metadata, execution and output delivery; automation tools launched in 2019.
- **ARIA** — Data exploration and harmonization for genomic and clinical information; commercial launch announced in October 2021.
- **Scientific and bioinformatics services** — Expert support for developing pipelines, harmonizing data, designing analyses and implementing custom automation.
- **CAVATICA and BioData Catalyst implementations** — Research environments using Seven Bridges technology for pediatric research and heart, lung, blood and sleep research respectively.

## Achievements

- Awarded a USD 5.8 million NCI Cancer Genomics Cloud pilot contract in 2014.
- Received an approximately GBP 1.95 million UK SBRI award for Graph Genome development in 2015.
- Named to MIT Technology Review’s 2016 50 Smartest Companies list, as reported in its press archive.
- Reported 260% annual contract value growth and 95% renewal rate for 2018; company figures.
- Published graph-based genomic analysis research in Nature Genetics in 2019.
- Seven Bridges technology continues within Velsera’s commercial platform and public research environments.

## Latest updates

- **2023-01** — Seven Bridges, Pierian and UgenTec combined to form Velsera, backed by Summa Equity.
- **2025-06** — Parent company Velsera announced its Global Data Network for longitudinal clinicogenomic data access; this is a Velsera portfolio update.
- **2025-07** — Velsera published a RHEO automation example integrating a clinical lab’s sequencer, cloud storage, metadata-dependent decisions and result delivery.
- **2026-01** — Velsera announced Jamie Coffin as CEO, effective February 1, 2026.
- **2026-05** — Velsera announced Kareem Saad as president and chief business officer.

## Links

- Website: https://www.sevenbridges.com/
- LinkedIn: https://www.linkedin.com/company/seven-bridges-inc
- Twitter/X: https://twitter.com/SevenBridges
- GitHub: https://github.com/sbg
- YouTube: https://www.youtube.com/@Velsera
- Facebook: https://www.facebook.com/pg/SevenBridgesGenomics/

---

Profile page: https://yespress.io/seven-bridges
Published by YesPress — https://yespress.io
Last updated: 2026-09-30